Medimpact

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

GANAXOLONE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
GANAXOLONE	ZTALMY	47912		GPI-10	
				(7260003300)	

GUIDELINES FOR USE

- 1. Does the patient have a diagnosis of seizures and meet **ALL** of the following criteria?
 - The patient is 2 years of age or older
 - The patient's seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD)

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #36 mL per day.** If no, do not approve.

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **GANAXOLONE (Ztalmy)** requires the following rule(s) be met for approval:

- A. You have seizures
- B. You are 2 years of age or older
- C. Your seizures are associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD: a type of genetic disorder)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ztalmy.

REFERENCES

• Ztalmy [Prescribing Information]. Radnor, PA: Marinus Pharmaceuticals, Inc.; June 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Commercial Effective: 10/01/22 Created: 08/22 Client Approval: 09/22

P&T Approval: 07/22

Copyright © 2022 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.